This was a randomized study including 261 patients treated with infrapatellar percutaneous transluminal angioplasty.173 of these patients received an everolimus bioresorbable scaffold while the remaining 88 were treated with balloon angioplasty. The efficacy primary end point was limb salvage and primary patency rates at 12 months and the safety primary end point was freedom from…